Get the Daily Brief
Latest Biotech News
FDA postures on drug safety via court rulings and antitrust liability
The U.S. Supreme Court issued a unanimous ruling in Hikma’s favor in a “skinny label” patent case involving Amarin’s Vascepa, clearing the pathway for generic competition under indication-specific...
Biotech funding and business development accelerate clinical pipelines
Ona Therapeutics raised $86.6 million in a series B to advance antibody-drug conjugate (ADC) programs in advanced cancers, with its lead asset ONA-255 progressing through clinical development in...
Clinical and trial outcomes reshape oncology risk calculus
Zynlonta’s confirmatory Phase 3 readout in DLBCL undermined the path to full approval, with ADC Therapeutics reporting 27 deaths in the treatment arm versus nine in the control arm and no overall...
Ebolavirus diagnostics ramp up for outbreak control
The World Health Organization unveiled a six-month plan to stamp out the current Bundibugyo Ebola virus outbreak, including a scale-up of point-of-care molecular diagnostics supplied through KH...
AI and automation for clinical development and diagnostics operations
Medable launched its Agentic Accelerator Program to help life sciences companies deploy agentic AI in clinical development. The offering includes onboarding, integration support, governance, and...
Strategic partnerships to move cell and gene therapy distribution
Cencora agreed to partner with Kite to distribute Kite’s FDA-approved CAR T-cell therapies Yescarta and Tecartus across the U.S. The collaboration is aimed at expanding patient access at...
Diagnostic expansion via acquisition in bladder cancer risk testing
Photocure signed an agreement to acquire Vesica Health for $30.5 million, adding AssureMDx, a urine-based molecular test, to its bladder cancer portfolio. Photocure said AssureMDx uses...
Biopharma legal and compliance signals tied to AI and governance safeguards
A coalition of technology and biotech leaders backed an open call for mandatory screening and recordkeeping of synthetic DNA orders. The letter’s signatories include companies and organizations...
Substantial employment and market structure shifts in a major biotech hub
A new MassBioEd employment outlook report found Massachusetts’ life sciences workforce dipped 1% in 2025 after 14 years of growth, to 143,224 jobs. The report projects a rebound with 9.7% growth...
Ebola diagnostics and outbreak response scale-up
WHO unveiled a six-month plan to curb the current Bundibugyo Ebola outbreak in Africa, pairing surveillance expansion with a major diagnostic scale-up. Africa CDC, FIND, Unitaid and local...
Regulatory and policy pressure on drug review speed and pricing mechanisms
The U.S. House Appropriations Committee directed FDA to speed up IND sign-off processes, framing the change as necessary to help the U.S. keep pace with China and other nations developing new...
FDA skinny-label patent victory for generic Vascepa
The U.S. Supreme Court unanimously ruled in favor of Hikma Pharmaceuticals in a key “skinny label” case involving Amarin’s Vascepa, affirming that Hikma’s generic did not infringe Amarin’s patents...
Strategic financing and corporate moves in oncology and platform technologies
On the venture side, Ona Therapeutics raised $86.6 million in a funding round to advance ADC programs focused on drug resistance and advanced breast cancer. The financing supports continued...
Biopharma dealmaking: licensing and partnerships
Agios Pharmaceuticals agreed to a potential $665 million deal that shifts focus onto cancer therapy resistance after gaining global rights to Oscotec’s cevidoplenib, described as a phase III-ready...
Clinical setbacks and risk reassessment in late-stage development
ADC Therapeutics disclosed top-line confirmatory Phase 3 data for Zynlonta (loncastuximab tesirine) plus rituximab in relapsed or refractory DLBCL, with increased death counts in the treatment arm...
FDA/Regulatory actions and compliance watch: CNPV and CMS pricing rules
The debate over accelerated review continues as stakeholders urged FDA to pause its Commissioner’s National Priority Voucher program during a June 4 listening session. Companies and patient groups...
AI-enabled life-sciences tools: protein characterization and clinical development workflows
Bio-Techne and Refeyn announced an integrated workflow combining MauriceFlex imaged capillary isoelectric focusing (icIEF) with Refeyn’s TwoMP mass photometry to characterize charge and size...
Diagnostics and imaging innovation for oncology and disease risk stratification
New diagnostic and imaging tools continue to move toward earlier detection and more precise risk stratification. Photocure’s acquisition of Vesica Health further expands the urine molecular...
Biotech finance and funding momentum
Biopharma financing remains active, with total funding through early June reported at $49.46 billion, more than doubling the same period in 2025. The data point to a stronger capital appetite,...
Regulatory / Public health diagnostics scale-up for Ebola
The World Health Organization laid out a six-month plan to contain the current Bundibugyo ebolavirus outbreak in Africa, including a major scale-up of point-of-care molecular diagnostics. WHO said...